This year, for the first time, two teenagers in Florence, South Carolina, are going to be able to go swimming…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
This month, the University of Tennessee Health Science Center College of Nursing is hosting a conference that aims to educate…
Scientists have discovered more than a dozen genes that regulate the production of fetal hemoglobin in people of African descent,…
Undergoing a bone marrow transplant during adolescence may reduce the risk of stroke in people with sickle cell disease…
AÂ sickle cell disease (SCD) patient in Bahrain received the gene-editing therapy Casgevy (exagamglogene autotemcel), becoming the first patient…
Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell…
The Bill and Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support the development…
A newborn screening program in Catalonia improved outcomes for children with sickle cell disease (SCD), with patients being…
Most people with sickle cell disease (SCD) who received the gene-editing therapy Casgevy (exagamglogene autotemcel) in clinical trials…
The vast majority of people with sickle cell disease (SCD) who received the now-approved gene therapy Lyfgenia (lovotibeglogene…